We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you. We are currently recruiting for two Warehouse Controllers to join the Warehouse and Supply Chain (WSC) team. One of these roles will be based at our Wallingford site, and one will be based out of our OxBox facility, please indicate on your applicaiton which site you would like to be based at. The purpose of the role is to carry out all the necessary activities to support the warehouse “end to end” function. This includes the physical receipt of materials, booking in, labelling and movement to picking against shop orders, packing, and delivering to production facilities. Our warehouse and supply chain team are critical to our Manufacturing success. They make sure we have the consumables and reagents needed to make our products, which will go on to change the lives of millions of patients. This multi-functional team works together to support all our logistical needs. Your responsibilities in this role would be: • Receive stock from vendors, ensuring product is: • Delivered without damage • At correct location address and matches purchase order • Stored in appropriate location (noting any special temperature/hazardous storage conditions). • Ensure stock is in correct storage areas (Quarantine; Release; Reject) • Updating of computer system where applicable to ensure accuracy. • Ensure accuracy of stock is maintained – by performing cycle counting/stock checks • Ensure cleanliness, safety and security of warehouse is always maintained • Maintain and update Standard Operating Procedures to reflect current practices. • Pick, pack check stock by item, batch number and quantity as requisition. • Drive company vehicle to deliver requisitions to production and OXB (Oxford Biomedica) sites • Raise purchase requisitions where appropriate We are looking for: • High degree of accuracy, numeracy, and literacy • Computer literacy (Word, Excel & Microsoft Outlook & Teams) • Previous warehouse experience essential • Manual handling trained • Experienced in operating mechanical lifting (FLT not essential) • Driving licence essential About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Responsible, Responsive, Resilient, Respect • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.